📊 XFOR Key Takeaways
Is X4 Pharmaceuticals, Inc (XFOR) a Good Investment?
X4 Pharmaceuticals faces fundamental operational collapse with revenue down 81.5% YoY to just $2.5M, while burning $19.6M quarterly in operating cash. Despite a strong balance sheet with $216.9M cash, the company's core business has failed catastrophically and cannot sustain current operations without significant strategic change or acquisition.
X4 Pharmaceuticals, Inc Key Strengths (XFOR)
- Strong cash position ($216.9M) provides 4+ years of runway at current burn rate
- Excellent liquidity ratios (10.18x current, 10.15x quick) with minimal near-term solvency risk
- Moderate leverage (0.45x debt/to-equity) provides some financial flexibility for restructuring
XFOR Stock Risks: X4 Pharmaceuticals, Inc Investment Risks
- Revenue collapsed 81.5% YoY to $2.5M indicating fundamental business/product failure
- Operating cash burn of $19.6M per quarter with minimal revenue is unsustainable
- Operating losses of $20.3M exceed revenue 8x fold, suggesting core business model broken
- Negative interest coverage (-3.1x) means company cannot service debt from operations
- Zero insider Form 4 filings in 90 days suggests no confidence from management despite distressed position
Key Metrics to Watch
- Quarterly revenue trend and stabilization point
- Operating cash flow improvement and path to cash-flow breakeven
- Cash burn rate and runway to depletion without strategic action
- New product pipeline updates and regulatory approvals
- Management insider buying activity and strategic announcements
X4 Pharmaceuticals, Inc (XFOR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 10.18x current ratio provides a solid financial cushion.
XFOR Profit Margin, ROE & Profitability Analysis
XFOR vs Healthcare Sector: How X4 Pharmaceuticals, Inc Compares
How X4 Pharmaceuticals, Inc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is X4 Pharmaceuticals, Inc Stock Overvalued? XFOR Valuation Analysis 2026
Based on fundamental analysis, X4 Pharmaceuticals, Inc shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
X4 Pharmaceuticals, Inc Balance Sheet: XFOR Debt, Cash & Liquidity
XFOR Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: X4 Pharmaceuticals, Inc's revenue has grown significantly by 1,070% over the 5-year period, indicating strong business expansion. The most recent EPS of $-17.07 indicates the company is currently unprofitable.
XFOR Revenue Growth, EPS Growth & YoY Performance
XFOR Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $2.7M | $282.0K | $0.04 |
| Q3 2025 | $560.0K | $282.0K | $0.35 |
| Q2 2025 | $563.0K | $282.0K | $-3.47 |
| Q1 2025 | N/A | $282.0K | $0.04 |
| Q2 2024 | $700.0K | -$24.0M | $0.19 |
| Q3 2021 | N/A | -$11.1M | N/A |
| Q2 2021 | N/A | -$11.1M | N/A |
| Q1 2021 | N/A | -$11.1M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
X4 Pharmaceuticals, Inc Dividends, Buybacks & Capital Allocation
XFOR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for X4 Pharmaceuticals, Inc (CIK: 0001501697)
📋 Recent SEC Filings
❓ Frequently Asked Questions about XFOR
What is the AI rating for XFOR?
X4 Pharmaceuticals, Inc (XFOR) has an AI grade of D with 90% confidence, based on fundamental analysis of SEC EDGAR filings.
What are XFOR's key strengths?
Claude: Strong cash position ($216.9M) provides 4+ years of runway at current burn rate. Excellent liquidity ratios (10.18x current, 10.15x quick) with minimal near-term solvency risk.
What are the risks of investing in XFOR?
Claude: Revenue collapsed 81.5% YoY to $2.5M indicating fundamental business/product failure. Operating cash burn of $19.6M per quarter with minimal revenue is unsustainable.
What is XFOR's revenue and growth?
X4 Pharmaceuticals, Inc reported revenue of $2.5M.
Does XFOR pay dividends?
X4 Pharmaceuticals, Inc does not currently pay dividends.
Where can I find XFOR SEC filings?
Official SEC filings for X4 Pharmaceuticals, Inc (CIK: 0001501697) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is XFOR's EPS?
X4 Pharmaceuticals, Inc has a diluted EPS of $-0.16.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is XFOR's fundamental grade?
Based on our AI fundamental analysis in June 2026, X4 Pharmaceuticals, Inc has a D grade with 90% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is XFOR stock overvalued or undervalued?
Valuation metrics for XFOR: ROE of -12.0% (sector avg: 15%), net margin of -809.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is XFOR's AI grade for 2026?
Our dual AI analysis gives X4 Pharmaceuticals, Inc a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is XFOR's free cash flow?
X4 Pharmaceuticals, Inc's operating cash flow is $-19.6M, with capital expenditures of $0.0. FCF margin is -784.0%.
How does XFOR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -809.6% (avg: 12%), ROE -12.0% (avg: 15%), current ratio 10.18 (avg: 2).